Rhabdomyolysis Due to Micronized Fenofibrate : The Endocrinologist

Journal Logo

Case Report

Rhabdomyolysis Due to Micronized Fenofibrate

Oguzhan, Nilufer MD; Unal, Aydin MD; Sipahioglu, Murat Hayri MD; Tokgoz, Bulent Prof.; Oymak, Oktay Prof.; Utas, Cengiz Prof.

Author Information
The Endocrinologist 20(6):p 288-289, November 2010. | DOI: 10.1097/TEN.0b013e3181fd0370


Fenofibrate, a fibric acid derivative, is frequently used to treat diabetic dyslipidemia and hypertriglyceridemia alone or in combination with statins. Rhabdomyolysis is a syndrome that results from striated muscle necrosis and release of its contents into the systemic circulation and extracellular fluid. Fenofibrate-induced rhabdomyolysis is a rare clinical condition if there is not a predisposing factor such as diabetes mellitus, hypothyroidism, and renal insufficiency. In this study, we present a case of a patient who developed rhabdomyolysis after micronized fenofibrate use without known predisposing factor.

© 2010 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Access through Ovid